In particular, the phase II LEAP-004 study, evaluating combined lenvatinib and pembrolizumab in 103 patients with advanced melanoma progressing on ICI, showed an ORR of 21.4%, reaching up to 33.3% in patients previously treated with anti-PD-1 and anti-CTLA-4 combination therapy. Here, CTLA4 is linked to melanoma.